Post by Manasee Kurlekar

One theme cuts across the entire July 2026 issue of BioSpectrum India : the country is done being the world's low-cost workshop. The conversation has moved to ownership — of enzymes, of IP, of the value chain itself. Our cover story, #Biocatalyst #Leadership: How #Enzymes Are Propelling India's Pharma, is the clearest signal of that shift. Enzymes have gone from invisible manufacturing aids to strategic assets in #API, #biologics, #vaccine and #biosimilar production — yet 70–80% are still imported. Prashant Nagre ( Fermenta Biotech Limited ) and Yatinkumar Wani ( Biolaxi Corporation ) lay out exactly where the gaps — and the #opportunities — sit. What else is in this edition: TRENDS — Pharma Fermentation: India's next biomanufacturing bet. With voices from Eppendorf , StrainX Bioworks , Syngene International Limited , Concord Biotech Limited , Frost & Sullivan and Raay Neo Pharma on why #fermentation could do for #biotech what IT did for India's digital economy. OUTLOOK — True self-reliance in molecular biology, featuring Molbio Diagnostics , MedGenome Labs Private Ltd. and Roche Diagnostics (I) Private Limited., on the hard truth that a "Make-in-India" kit still runs on imported #Polymerases . — plus a deep-dive on how #M&A is redrawing Indian pharma's global map (Sun–Organon and beyond) with OPPI India , ICRA , Cyril Amarchand Mangaldas , Grant Thornton Bharat LLP , Khaitan & Co and more. LEADERSHIP INTERVIEWS that matter: ▪️Sarvesh Mutha , MD, IntegriMedical — why needle-free delivery is aligning with where healthcare is headed ▪️ Tony Qiu , Head of APAC, Merck Life Science — the Peenya expansion and India's rise as a bioprocessing hub ▪️Radhakrishnan Srinivas , Commercial Head, Tecan India — why now was the moment for a direct India presence OPINION from Frost & Sullivan on why India's next healthcare shift will be decentralised by design — and a Let's Talk Health look at the race to end hepatitis by 2030. The strategic read is simple: the demand is here, the policy tailwinds (BioE3, PLI, Biopharma SHAKTI) are real, and the capital is moving. #Execution is now the only variable that counts. Read the full edition → https://lnkd.in/de8w3BWg #BioSpectrumIndia #LifeSciences #Pharma #Biotechnology #Enzymes #Fermentation #Diagnostics #Biomanufacturing #Innovation